#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14098	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2162	647.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1552	1552	C	812	C	761	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25528	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3651	697.1	0	.	n	.	0	T695C	SNP	695	695	T	1083	1083	C	737	C,T,A	699,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25528	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3651	697.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1725	1725	A	884	A,G	842,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25528	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3651	697.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2359	2359	C	804	C	760	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25528	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3651	697.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2433	2433	A	824	A	770	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25528	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3651	697.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2985	2985	C	789	C,T	740,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25528	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3651	697.1	0	HET	.	.	.	G2813A	.	2813	2813	G	3201	3201	G	813	G,A	574,204	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1888	folP	852	852	100.0	folP.l15.c4.ctg.1	1584	118.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1071	1073	AGC	188;187;185	A;G;C,T	182;180;176,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4998	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3367	148.0	1	SNP	p	S91F	0	.	.	271	273	TCC	523	525	TCC	181;176;176	T;C,T;C	163;159,1;161	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4998	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3367	148.0	1	SNP	p	D95G	0	.	.	283	285	GAC	535	537	GAC	166;167;168	G,A;A,G;C	150,1;152,1;154	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4998	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3367	148.0	1	SNP	p	D95N	0	.	.	283	285	GAC	535	537	GAC	166;167;168	G,A;A,G;C	150,1;152,1;154	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1566	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1498	104.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	628	630	ACC	182;182;183	A,G;C;C	162,1;169;172	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1566	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1498	104.2	0	.	p	.	0	R44H	NONSYN	130	132	CGC	643	645	CAC	181;183;184	C;A,G;C	169;167,1;172	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1566	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1498	104.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	826	828	CAC	208;210;208	C;A;C	188;190;189	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1566	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1498	104.2	1	SNP	p	G45D	0	.	.	133	135	GGC	646	648	GGC	185;187;188	G;G;C	172;174;174	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	930	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1155	80.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2871	173.8	1	SNP	p	D86N	0	.	.	256	258	GAC	542	544	GAC	217;215;216	G;A;C	207;203;201	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2871	173.8	1	SNP	p	S87I	0	.	.	259	261	AGT	545	547	AGT	214;214;216	A;G;T	202;202;203	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2871	173.8	1	SNP	p	S87W	0	.	.	259	261	AGT	545	547	AGT	214;214;216	A;G;T	202;202;203	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2871	173.8	1	SNP	p	S87R	0	.	.	259	261	AGT	545	547	AGT	214;214;216	A;G;T	202;202;203	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2871	173.8	1	SNP	p	S88P	0	.	.	262	264	TCC	548	550	TCC	216;215;213	T;C;C	203;199;200	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4190	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2699	154.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1579	1581	GGC	222;220;219	G;G;C	208;205;203	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1277	1279	GCA	203;202;203	G;C;A	186;187;189	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1280	1282	ATC	204;208;205	A;T;C	188;194;191	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1292	1294	GTG	196;194;198	G;T;G	183;178;184	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1292	1294	GTG	196;194;198	G;T;G	183;178;184	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1796	1798	ACC	183;182;183	A;C;C	171;173;175	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1850	1852	GCG	180;179;178	G;C;G	169;155;159	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1850	1852	GCG	180;179;178	G;C;G	169;155;159	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1973	1975	GGC	137;132;134	G;G;C	134;124;130	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1982	1984	GGC	132;132;129	G,C;G,C;C	124,1;123,1;123	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2444	151.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2000	2002	CCG	115;115;113	C,G;C;G	78,4;81;78	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5700	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3134	181.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2242	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1891	118.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	632	632	C	151	C	137	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	0	.	p	.	0	I45V	NONSYN	133	135	ATT	411	413	GTT	212;211;209	G;T;T	202;200;201	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	0	.	p	.	0	I75V	NONSYN	223	225	ATT	501	503	GTT	248;246;246	G;T;T	222;212;221	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	0	.	p	.	0	S89T	NONSYN	265	267	AGC	543	545	ACC	252;250;250	A;C;C	213;222;228	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	0	.	p	.	0	I98V	NONSYN	292	294	ATC	570	572	GTC	253;255;252	G;T;C	223;221;223	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	0	.	p	.	0	Y213_N214insRYAYRYAY	INS	637	637	T	915	915	T	189	T	179	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	1	SNP	p	G120K	1	.	.	358	360	AAG	636	638	AAG	246;245;246	A;A;G	233;231;231	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	1	SNP	p	A121N	1	.	.	361	363	AAC	639	641	AAC	243;245;248	A,G;A;C	229,1;231;236	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	1	SNP	p	N121D	0	.	.	361	363	AAC	639	641	AAC	243;245;248	A,G;A;C	229,1;231;236	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	0	HET	.	.	.	G628GGATATGCATATAGATATGCATATAGATATGCATATA,GGATATGCATATAGATATGCATATA	.	628	628	G	906	906	G	230	GGATATGCATATAGATATGCATATAGATATGCATATA,GGATATGCATATAGATATGCATATA	106,49	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	667	2904	porB1b	1038	1038	97.27	porB1b.l15.c4.ctg.1	1542	187.3	0	HET	.	.	.	A639AG	.	639	639	T	930	930	A	229	AG,A	174,23	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9798	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4759	205.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1930	1932	AAT	223;222;221	A,C;A;T	210,1;211;209	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1112	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	974	113.0	1	SNP	p	V57M	1	.	.	169	171	ATG	488	490	ATG	235;238;234	A;T;G	222;226;226	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
